Jay Olson
Stock Analyst at Oppenheimer
(3.48)
# 866
Out of 4,843 analysts
244
Total ratings
40.41%
Success rate
6.34%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Downgrades: Perform | n/a | $4.59 | - | 14 | May 27, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $65 | $28.34 | +129.36% | 1 | May 21, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $80 → $65 | $5.50 | +1,081.82% | 5 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $15 → $13 | $2.00 | +550.00% | 3 | May 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $75 | $39.40 | +90.36% | 9 | May 8, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $25 → $21 | $1.71 | +1,128.07% | 2 | May 7, 2025 | |
| NKTR Nektar Therapeutics | Upgrades: Outperform | $6 | $0.72 | +728.16% | 6 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $50 → $42 | $13.24 | +217.22% | 4 | Mar 3, 2025 | |
| EXEL Exelixis | Downgrades: Perform | $41 → $33 | $43.04 | -23.33% | 6 | Jan 24, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $60 → $40 | $6.87 | +482.24% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $1.73 | +1,056.07% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $3.55 | +745.07% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $3.11 | +543.09% | 2 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $255 | $129.79 | +96.47% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $9 → $8 | $6.46 | +23.84% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $65.06 | +26.04% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $275.26 | +27.15% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $3.07 | +225.73% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $26.80 | +414.93% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.77 | +351.98% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 | $8.22 | +483.94% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $288.18 | +31.86% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $123.02 | +78.02% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $1.72 | +597.67% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $2.74 | +556.93% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.90 | +1,013.96% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $36.29 | +161.78% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $19 | $21.57 | -11.91% | 14 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.98 | +1,162.63% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $33.51 | +123.81% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.24 | +3,665.69% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $9.84 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $50 | $1.04 | +4,707.69% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $5.91 | +255.63% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.75 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $21.96 | +282.51% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.46 | - | 3 | Jul 11, 2017 |
Prothena Corporation
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $4.59
Upside: -
Tvardi Therapeutics
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $28.34
Upside: +129.36%
Jasper Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $5.50
Upside: +1,081.82%
Inovio Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $2.00
Upside: +550.00%
Revolution Medicines
May 8, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $39.40
Upside: +90.36%
Immuneering
May 7, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $1.71
Upside: +1,128.07%
Nektar Therapeutics
Mar 14, 2025
Upgrades: Outperform
Price Target: $6
Current: $0.72
Upside: +728.16%
Denali Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $13.24
Upside: +217.22%
Exelixis
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $43.04
Upside: -23.33%
Intellia Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $6.87
Upside: +482.24%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $1.73
Upside: +1,056.07%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $3.55
Upside: +745.07%
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $3.11
Upside: +543.09%
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $129.79
Upside: +96.47%
Oct 30, 2024
Maintains: Perform
Price Target: $9 → $8
Current: $6.46
Upside: +23.84%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $65.06
Upside: +26.04%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $275.26
Upside: +27.15%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $3.07
Upside: +225.73%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $26.80
Upside: +414.93%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.77
Upside: +351.98%
Aug 7, 2024
Maintains: Outperform
Price Target: $48
Current: $8.22
Upside: +483.94%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $288.18
Upside: +31.86%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $123.02
Upside: +78.02%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $1.72
Upside: +597.67%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $2.74
Upside: +556.93%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.90
Upside: +1,013.96%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $36.29
Upside: +161.78%
May 6, 2024
Maintains: Perform
Price Target: $19
Current: $21.57
Upside: -11.91%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $1.98
Upside: +1,162.63%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $33.51
Upside: +123.81%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.24
Upside: +3,665.69%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $9.84
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $120 → $50
Current: $1.04
Upside: +4,707.69%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $5.91
Upside: +255.63%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.75
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $21.96
Upside: +282.51%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.46
Upside: -